Atypicality of several antipsychotics on the basis of in vivo dopamine-D2 and serotonin-5HT2 receptor occupancy

Get rights and content

An in vivo receptor binding technique was used to evaluate the binding profiles of typical and atypical antipsychotic drugs to striatal dopamine-D2 and frontal serotonin-5-HT2 receptors in a rat brain using more specific ligands than those previously employed. [3H]-YM-09151-2 or [3H]-ketanserin was injected into the tail vein 10 minutes after administration of test drugs. One hour after the ligand injection, radioactivities in the striatum, frontal cortex, and cerebellum were counted to obtain receptor occupancies by the test drugs. Higher ratios of potency in occupying 5-HT2 versus D2 receptors were found for clozapine, RMI-81512, and tiospirone compared to haloperiodol and pimozide. Zotepine, mosapramine, and clocapramine produced ratios that fall between these two groups. Chlorpromazine was exceptional as a typical antispychotic by these criteria. Relatively strong antagonism of 5-HT2 receptors by atypical antipsychotics was confirmed by this in vivo measure of receptor binding using more selective ligands than those used in previous studies.

References (42)

  • CreeseI et al.

    Dopamine receptor binding predicts clinical and pharmacological potencies of anticholinergic drugs

    Science

    (1976)
  • FleischhackerWW et al.

    Zotepine vs. haloperidol in paranoid schizophrenia: A double-blind trial

    Psychopharmacol Bull

    (1989)
  • GeldersYG

    Thymosthenic agent, a novel approach in the treatment of schizophrenia

    Schizophr Res

    (1989)
  • HatanoK et al.

    D2-dopamine receptor specific brain uptake of carbon-11-labeled YM-09151-2

    J Nucl Med

    (1989)
  • KahnRS et al.

    Serotonin, dopamine and their interactions in schizophrenia: an editorial

    Psychopharmacology

    (1993)
  • KaneJM et al.

    Clozapine for the treatment-resistant schizophrenics: A double-blind comparison with chlorpromazine

    Arch Gen Psychiatry

    (1988)
  • KuriharaM et al.

    Clinical evaluation of clocapramine (ClofektonR) in schizophrenia: A double blind comparison of clocapramine, haloperidol and perphenazine

    Clin Psychiat

    (1983)
  • LeysenJE et al.

    In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone

    Mol Pharmacol

    (1992)
  • LeysenJE et al.

    Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: Role of 5HT2 receptors

    Psychopharmacology

    (1993)
  • MatsubaraS et al.

    Dopamine D1, D2 and serotonin2 receptor occupation by typical and atypical antipsychotic drugs in vivo

    J Pharmacol Exp Ther

    (1992)
  • MeltzerHY et al.

    Classification of typical and atypical antipsychotic drugs on the basis of dopamine D1, D2 and serotonin2 pKi values

    J Pharmacol Exp Ther

    (1989)
  • Cited by (58)

    • Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases

      2019, European Journal of Medicinal Chemistry
      Citation Excerpt :

      This compound contains a fully saturated imidazo[1,2-a]pyridine core. In addition to targeting dopamine receptors, it also binds to 5-HT2ARs, thus expending a concept of atypical antipsychotics [92,93]. Since the imidazopyridine-derived core is unlikely to be a key fragment for interaction with dopamine receptor, the main pharmacophore is attributed to a 7-membered nitrogen-containing ring.

    • Antipsychotic drugs dose-dependently suppress the spontaneous hyperactivity of the chakragati mouse

      2010, Neuroscience
      Citation Excerpt :

      The drugs administered were vehicle, haloperidol (0.03, 0.1, 0.3, 1 and 3 mg/kg), pimozide (0.03, 0.1, 0.3, 1 and 3 mg/kg), risperidone (0.01, 0.03, 0.1, 0.3 and 1 mg/kg), clozapine (0.1, 0.3, 1, 3 and 10 mg/kg), olanzapine (0.6, 2, 6 and 20 mg/kg), ziprasidone (1, 3, 10, 30 and 100 mg/kg), quetiapine (6, 20, 60 and 200 mg/kg) or aripiprazole (1.67, 3, 5, 10, 15 and 30 mg/kg). As the pharmacokinetics of antipsychotics differ in rodents and humans, doses of the test compounds were selected to include doses that would approximate to 60–80% maximal D2 receptor occupancy in the rodent and thus correspond to receptor occupancy on human clinical dosing (Assié et al., 2006; Kapur et al., 2003; Sumiyoshi et al., 1995): 0.03–1 mg/kg haloperidol, 3 mg/kg pimozide, 1 mg/kg risperidone, 10 mg/kg clozapine, 2 mg/kg olanzapine, 1 mg/kg ziprasidone, 20 mg/kg quetiapine and 5 mg/kg aripiprazole. Haloperidol, pimozide, risperidone and clozapine were tested in the first batch of 32 ckr mice and olanzapine, ziprasidone, quetiapine and aripiprazole were tested in the second batch of 26 ckr mice.

    View all citing articles on Scopus
    1

    From the Department of Neuropsychiatry (TS, KS, HS, NY) of Kanazawa, University School of Medicine, Kanazawa 920, Japan

    2

    Radioisotope Center (HM, KS) of Kanazawa, University School of Medicine, Kanazawa 920, Japan

    3

    Hospitals Pharmacy (KY) of Kanazawa, University School of Medicine, Kanazawa 920, Japan

    View full text